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HLA-matched related donor (MRD) hematopoietic stem cell transplantation (HSCT) is a well-established
therapy for patients with sickle cell disease (SCD); however, experience using alternative donors, including
haploidentical donors, in HSCT for SCD is limited. We report the long-term outcomes of 22 pediatric patients
who underwent related donor HSCT for SCD at St. Jude Children’s Research Hospital, either a myeloablative
sibling MRD HSCT (n ¼ 14) or reduced-intensity parental haploidentical donor HSCT (n ¼ 8). The median
patient age was 11.0  3.9 years in the MRD graft recipients and 9.0  5.0 years in the haploidentical donor
graft recipients. The median follow-up was 9.0  2.3 years, with an overall survival (OS) of 93% and
a recurrence/graft failure rate of 0%, for the MRD cohort and 7.4  2.4 years, with an OS of 75%, disease-free
survival of 38%, and disease recurrence of 38%, for the haploidentical donor cohort. We report the long-term
hematologic response and organ function in patients undergoing MRD or haploidentical donor HSCT for
severe SCD. Our data demonstrate long-term hematologic improvements after HSCT with sustained
engraftment, and conﬁrm that HSCT offers long-term protection from common complications of SCD,
including stroke, pulmonary hypertension, acute chest, and nephropathy, regardless of donor source.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION These early reports suggest the potential for using a reduced-
Currently allogeneic hematopoietic stem cell trans-
plantation (HSCT) is the sole curative option for sickle cell
disease (SCD). The majority of HSCTs performed for SCD
involve transplantation of HLA-matched related donor
(MRD) grafts after a myeloablative preparative regimen.
Several previous studies have reported excellent outcomes in
recipients of MRD HSCT for SCD, with >80% disease-free
survival (DFS) and >90% overall survival (OS) [1-4]. More-
over, recipients who achieve durable engraftment of donor
cells do not experience the continual vaso-occlusive damage
related to SCD [3-9].
Although these results are encouraging, 85% of patients
with SCD who meet the criteria for an HSCT do not have an
appropriate MRD [10]. This lack of MRD availability has been
a major barrier to HSCT for patients with severe SCD.
Recently, alternative donor sources for HSCT, including cord
blood and HLA-haploidentical donors, have been explored
for patients with SCD [11,12].
Bolaños-Meade et al. [11] recently reported the outcomes
of 14 patients with SCD who underwent haploidentical
donor HSCT with a nonmyeloablative conditioning regimen.
Eight of the 14 patients engrafted and were asymptomatic at
a median follow-up of 2.1 years. Graft failure (43%) remained
a major obstacle, but no serious toxicities were reported.edgments on page 829.
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13.02.010intensity haploidentical HSCT platform to treat SCD. Further
studies on approaches to decreasing graft failure and
continual long-term follow-up are needed to establish hap-
loidentical donor HSCT as a safe, effective alternative treat-
ment for SCD.
The effects of MRD HSCT on other organs have been re-
ported through retrospective reviews of available data from
large multicenter studies [4-8,13-17]. Although comprehen-
sive neurocognitive studies performed after HSCT have re-
ported stable ﬁndings, no prospective evaluations performed
both before and after HSCT have been reported to date [7].
Moreover, long-term prospective imaging, neurocognitive,
and pulmonary function studies are needed in patients
with SCD undergoing reduced-intensity conditioning hap-
loidentical HSCT. Finally, pulmonary hypertension is associ-
ated with a high risk of mortality [18,19] and should be
followed in patients undergoing MRD HSCT or haploidentical
donor HSCT. A comprehensive evaluation of central nervous
system, pulmonary, cardiac, renal, endocrine, growth, and
gonadal toxicities in patients undergoing haploidentical
HSCT for SCD is currently just emerging. Here we report the
long-term outcomes of pediatric patients who underwent
reduced-intensity haploidentical donor HSCT or myeloa-
blative MRD HSCT, with similar hematologic responses and
organ function in patients with durable engraftment.MATERIALS AND METHODS
Patients
All 22 patients were enrolled in a St Jude Children’s Research Hospital
Institutional Review Boardeapproved study (SCALLO or FAMSCT/SCDHAP).Transplantation.
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each patient or a parent or guardian signed an Institutional Review
Boardeapproved informed consent form before receiving treatment on
a Phase II clinical trial registered at ClinicalTrials.gov (NCT00186810 and
NCT00152113). For MRD HSCT, patients age 21 years with symptomatic
SCD genotype SS, SC, or Sb0 with an MRD or related umbilical cord blood
(UCB) donor with hemoglobin genotype AA or AS were considered for HSCT.
HLA typing at the molecular level was performed, and all donors were fully
matched as described previously [20]. All patients were required tomeet the
eligibility criteria as reported previously, and any patient with extensive
end-organ damage was excluded [21]. An additional eligibility criterion for
patients undergoing haploidentical donor HSCT was a previous cerebro-
vascular accident (CVA).
Donors and Grafts
MRD grafts consisted of fresh harvested bone marrow (BM) with
a collection target of 4  108 total nucleated cells/kg. Cryopreserved
MRD cords blood units could be used as well. For haploidentical grafts,
preference was given to donors who were natural killer cell Ig-like
receptoremismatched with recipients. The haploidentical donor grafts
consisted of a granulocyte colony-stimulating factoremobilized apheresis
product that was CD34þ-selected, cryopreserved, and administered on day
0. The donor also underwent a second cycle of granulocyte colony-
stimulating factoreprimed apheresis to provide a fresh CD3þ-depleted
product to reach the CD34þ cell target dose of 5  106 cells/kg. Thus, the
product consisted of a CD34þ-selected product infused on day 0 and a CD3þ-
depleted product infused on day þ1 using the CliniMACS device, as
described previously [22,23]. A ﬁxed CD3þ Tcell dose of approximately 1.0
105 cells/kg was targeted for infusion.
HSCT Conditioning and GVHD Prophylaxis Regimens
For MRD HSCT, patients were conditioned with targeted busulfan,
cyclophosphamide (200 mg/kg), and horse antithymocyte globulin (20 mg/
kg). Busulfan was given i.v. or orally 4 times daily at a starting dose of 37.5
mg/m2 for 4 consecutive days. Busulfan concentrations was measured after
the ﬁrst dose, and subsequent doses were adjusted to achieve a targeted
systemic exposure with an area under the receiver-operating characteristic
curve of 6000 ng/mL/hr, equivalent to approximately 1500 uM. Busulfan
concentration was monitored daily throughout the course of therapy.
GVHD prophylaxis included cyclosporine beginning on day -2 and
methotrexate at 15 mg/m2 on days þ1, þ3, and þ6 and 10 mg/m2 on
day þ11. Patients receiving a UCB graft were given cyclosporine without
methotrexate. In patients who developed GVHD, methylprednisolone was
added at an initial dose of 1mg/kg and increased in the event of persistent or
progressive GVHD.
The ﬁrst 3 haploidentical HSCT recipients received ﬂudarabine (150-200
mg/m2), thiotepa (10 mg/kg), targeted busulfan (900 ng/mL for 4 days),
rabbit antithymocyte globulin (10 mg/kg for 3 days), and muromonab-CD3
(Orthoclone OKT3; 0.1 mg/kg maximum over days þ1 to þ20). The next 5
patients received hydroxyurea and azathioprine approximately 3 months
before HSCT, followed by busulfan (900 ng/mL for 4 days), thiotepa (10 mg/
kg), cyclophosphamide (200 mg/kg), and OKT3 (0.1 mg/kg maximum on
days -10 to þ17), as well as mycophenolate mofetil for GVHD prophylaxis.
Supportive Therapy
Patients who were not receiving long-term transfusion therapy under-
went a partial exchange transfusion to achieve a hemoglobin S fraction
30% before HSCT. Strategies to prevent neurologic complications included
anticonvulsant prophylaxis with phenytoin during busulfan administration
and continuing for 6 months after HSCT, along with strict control of
hypertension and magnesium levels. Hemoglobin concentration was
maintained at 9-11 g/dL, and platelet count was maintained at 50,000/mL.
Before HSCT, patients were started and maintained on oral penicillin V-K.
Oral trimethoprim and sulfamethoxazole was provided for Pneumocystis
jiroveci prophylaxis. Cytomegalovirus (CMV)-seropositive patients or
patients with a CMV-seropositive donor received acyclovir prophylaxis on
day þ1 to day þ120. Viral reactivation of CMV and Epstein-Barr virus were
monitored weekly for detection of DNA copy number by PCR. CMV reac-
tivation was treated with gancyclovir or foscarnet. Epstein-Barr virus reac-
tivation and lymphoproliferative disorder were treated with monoclonal
anti-CD20 antibody.
Engraftment and Donor Chimerism
Engraftment was deﬁned as the ﬁrst of 3 consecutive days with an
absolute neutrophil count (ANC) 500/mL. Hematopoietic cell chimerism
was identiﬁed by studies of restriction fragment-length polymorphisms or
variable number tandem repeats (VNTRs) in DNA. BM aspirates were ob-
tained at the time of engraftment or around day þ21. Peripheral bloodsamples for VNTR analysis were obtained starting at the appearance of signs
of ANC recovery or by day þ21, whichever occurred ﬁrst. Thereafter, VNTR
analysis was performed weekly up to day þ120, then monthly up to 1 year,
and then annually. After engraftment, patients with stable donor chimerism
who subsequently developed aplasia, cytopenia, or an ANC<500/mm3 were
eligible to receive an additional CD34þ stem cell “boost” of 5  106 CD34þ
cells/kg. In addition, patients with declining donor chimerism without
aplasia or cytopenia were eligible to receive up to 3 donor lymphocyte
infusions (DLIs) at 2.5 104 CD3þ cells/kg/dose in accordance with protocol.
Assessment of Disease Response and Organ Function
Before HSCT, patients underwent a complete blood count (CBC) with
WBC differential, platelet count, reticulocyte count, hemoglobin electro-
phoresis, and quantiﬁcation of hemoglobin F, A1, and S, ferritin, and iron.
CBC with WBC differential was performed a minimum of 3 times per week
until the ﬁrst hospital discharge after HSCT. Reticulocyte count, hemoglobin
electrophoresis, and quantiﬁcation of hemoglobin F, A1, and Swere obtained
yearly thereafter. Ferritin and iron levels weremeasured every 3months and
then annually after the patient had been transfusion-independent for 1 year.
Patients with evidence of iron overload and persistent elevated ferritin
levels after successful HSCT were considered for phlebotomy and/or chela-
tion therapy.
Transcranial Doppler (TCD) was performed before and at 6, 12, and 24
months after HSCT. Prospective magnetic resonance imaging (MRI),
magnetic resonance angiography (MRA), neuropsychological testing, and
neurologic examinations were performed on all patients before and at
day þ180 after HSCT, and yearly thereafter. Patients were imaged using
sagittal T1-, axial inversion recovery T2-, and FLAIR-weighted sequences on
a 1.5-T imager. Comprehensive neuropsychological evaluations were ob-
tained before and at 1, 3, and 5 years after HSCT. Neuropsychiatric evaluation
included age-appropriate assessment of intelligence or developmental
quotient for all patients. For patients of school age and older, comprehensive
assessment of academic achievement, attention, memory, visual-motor, and
visual-perceptual skills was performed.
All patients underwent organ function studies before HSCT. Pulmonary
function tests (PFTs), including total lung capacity, forced vital capacity
(FVC), and diffusion capacity of the lung for carbon monoxide (DLCO), were
performed yearly. Cardiac function was evaluated by echocardiography and
electrocardiography (ECG) annually. Renal functionwas assessed by 24-hour
urine protein and creatinine clearance (CrCl) and/or technetium 99m-
labeled diethylenetriamine penta-acetic acid (Tc99m DPTA) plasma clear-
ance at approximately day þ120 and annually thereafter. Liver biopsy
analysis, including measurement of liver iron content, was performed if the
ferritin level was >1000 mg/mL. Liver-spleen scans were performed at
approximately 3, 12, and 24 months after HSCT. Endocrine function tests,
including thyroid function tests and measurement of luteinizing hormone
(LH), follicle-stimulating hormone (FSH), estradiol, and testosterone, were
performed annually after HSCT. Bone age ﬁlms were obtained annually until
maturation. All patients underwent annual imaging studies by MRI and/or
plain ﬁlm of the hips to assess the risk of osteonecrosis. Bone mineral
density (BMD) and BMD z-score of the whole body and lumbar spine were
monitored yearly with computed tomography bone density and dual-
energy X-ray absorptiometry scans.
Statistical Analysis
Statistical analyses were performed to summarize results for the MRD
cohort. Descriptive results are provided for patients who underwent hap-
loidentical HSCT. The Kaplan-Meier method was used to estimate OS and
DFS; events studied included death, graft rejection, and recurrence of SCD.
The Student t-test was applied to each of variables to evaluate for any
signiﬁcant changes after HSCT. Descriptive statistics were computed for each
function variable.
RESULTS
Patients
Twenty-two patients with SCD underwent related donor
HSCT at St. Jude Children’s Research Hospital, including 14
recipients of a siblingMRD graft and 8 recipients of a parental
haploidentical donor graft (Table 1). Eighteen patients had
SCD-SS, 2 had SCD-SC, and 2had SCD-SB. TheMRDcohort had
a median age of 11.0  3.9 years (range, 5.4-17.4 years) and
included 3 females and 11 males. The indications for HSCT
included a history of stroke (9 patients), recurrent acute chest
syndrome (8 patients), and recurrent painful episodes (6
patients),withmost patients havingmultiple indications. The
Table 1
Patient and Graft Characteristics, Engraftment, GVHD, and Follow-Up
Patient Age, yr Sex Diagnosis Donor Indication HLA
Match
TNC, 
108/kg
CD3, 
106/kg
ANC,
Days
Graft aGVHD cGVHD Status Follow-
Up, yr
1 14.6 M SCD-SS MRD BM CVA/AC 6/6 4.64 12 Stable Grade
III
Severe lung Expired (1.2)
2 14.5 M SCD-SB MRD BM CVA/AC 6/6 3.20 16 Stable Grade II Moderate
GI
Alive 7.3
3 9.2 F SCD-SS MRD BM CVA/AC 6/6 3.23 17 Stable None None Alive 12.3
4 6 M SCD-SS MRD BM AC 6/6 5.75 19 Stable Grade I None Alive 6.1
5 10.5 M SCD-SS MRD BM TCD 6/6 2.14 15 Stable None None Alive 5.2
6 14.3 M SCD-SS MRD BM AC 6/6 2.85 24 Stable None None Alive 10.9
7 14.6 F SCD-SS MRD BM AC/TCD 6/6 3.29 15 Stable None None Alive 9.3
8 5.8 M SCD-SC MRD BM TCD 6/6 3.31 14 Stable None None Alive 5.9
9 5.4 M SCD-SS MRD BM CVA 6/6 3.94 28 Stable None None Alive 11.0
10 8.8 M SCD-SS MRD BM CVA 6/6 3.00 16 Stable None None Alive 12.2
11 13.7 M SCD-SS MRD BM CVA 6/6 3.21 23 Stable None None Alive 7.9
12 17.4 M SCD-SS MRD BM CVA /AC 6/6 3.29 14 Stable Grade II Moderate
GI
Alive 8.8
13 8.5 F SCD-SB MRD cord
blood
CVA/AC 6/6 0.45 23 Stable Grade I None Alive 6.0
14 11.5 F SCD-SS MRD BM TCD/AC 6/6 4.71 15 Stable Grade
III
None Alive 10.0
15 8.5 F SCD-SS Haplo; father CVA 3/6 0.32 0.009 12 Stable; DLI
on day þ107
None None Alive 8.9
16 6.9 M SCD-SS Haplo; father CVA 3/6 0.18 0.010 12 Rejection;
CD34 boost
None d Alive
with
SCD
7.8
17 13.4 M SCD-SB Haplo; father CVA 3/6 0.18 0.013 13 Stable after
rejection;
CD34 boost
Grade I None Alive 9.0
18 17.1 F SCD-SS Haplo; father CVA 3/6 4.52 0.168 11 Stable Grade I Extensive;
severe lung
Expired (0.9)
19 4.2 M SCD-SS Haplo; mother CVA 3/6 10.16 0.149 13 Stable Grade II Limited;
mild skin
Alive 6.9
20 16.9 M SCD-SB Haplo; mother CVA 3/6 1.541 0.100 14 Rejection;
DLI
on day þ51;
CD34 boost
None d Alive
with
SCD
3.7
21 5.8 M SCD-SS Haplo; father CVA 4/6 18.90 0.100 16 Rejection;
auto-HSCT
None d Alive
with
SCD
2.8
22 9.5 F SCD-SS Haplo; mother CVA 4/6 0.14 0.006 11 Stable; DLI
on day þ70
Grade II Extensive;
severe lung
Expired (2.3)
AC indicates acute chest; Haplo, haploidentical; TNC, total nucleated cells; CD34þ boost, 5  106-108 cells/kg; DLI dose, 0.025  106 CD3þ cells/kg.
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to 17 years) and included 3 females and 5 males. All the
patients had a history of symptomatic SCD and documented
CVA. The infused donor products had a mean total nucleated
cell count of 450  680  106 cells/kg (range, 10-1890  106/
kg), a CD34þ cell count of 25.416.3 106/kg (range, 6-57
106/kg), and a CD3þ cell count of 0.07 0.07 106/kg (range,
0.006-0.168  106/kg) (Table 1).
Outcome
After a median of 9.0 2.3 years (range, 5.9 to 12.3 years),
13 of the 14 patients in the MRD cohort were alive, at
a median age of 21  6.2 years (range, 12 to 33 years). One
patient died at 15 months post-HSCT from complications
related to chronic GVHD (cGVHD). Kaplan-Meier estimates of
OS and DFS were both 93%, and there were no cases of graft
failure/disease recurrence (Figure 1A).
After a median of 7.4  2.7 years (range, 2.8 to 9 years), 6
of the 8 patients (75%) were alive, at a median age of 216.2
years (range, 12 to 33 years). Three of the 8 patients (38%)
experienced sustained engraftment and remained disease-
free. Two patients (25%) died from complications related to
chronic GVHD, at 0.9 and 2.3 years after HSCT. Graft failure
and SCD recurrence occured in 3 patients (38%). Kaplan-
Meier estimates of OS and DFS were 75% and 38%, respec-
tively (Figure 1B).Engraftment and Chimerism
All MRD HSCT recipients engrafted; the median time to
engraftment with an ANC 500/mL was 16.0  4.7 days
(range, 15 to 32 days), and the median time to a platelet
count20,000/mL was 28.0 17.5 days (range,11 to 40 days).
At 5 years post-HSCT, all surviving patients demonstrated
sustained engraftment with 85% donor-derived blood cells
on chimerism tests.
All 8 haploidentical HSCT recipients achieved donor
engraftment with 100% donor chimerism, with a median
time to engraftment of 12.5  1.7 days (range, 10 to 14 days)
and a median time to a platelet count 20,000/mL of 19.0 
15.4 days (range, 17 to 49 days). Thereafter, 4 patients (50%)
developed evidence of graft rejection at a median of 30 days
(range, 22 to 44 days) and required additional stem cell
infusion. After this infusion, 1 of the 4 patients recovered
with sustained 100% donor chimerism, whereas the other 3
patients progressed to graft failure with recurrence of
disease. Donor engraftment was sustained in 5 patients
(62%), and graft failure occurred in 3 patients (38%).GVHD
Four MRD HSCT recipients (28%) developed grade II-IV
acute GVHD (aGVHD), and 3 patients (21%) developed
cGVHD. One patient with extensive or severe cGVHD of the
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Figure 1. Kaplan-Meier estimates of OS and DFS after MRD HSCT and haploidentical HSCT. OS and DFS were determined with events deﬁned as death, graft rejection,
or recurrence of SCD after MRD HSCT (A) or haploidentical HSCT (B). Tick marks represent surviving patients and indicate the duration of follow-up after trans-
plantation. The percentages above each curve indicate the estimates of OS, DFS, and cumulative incidence of graft rejection or recurrence of disease for the entire
cohort.
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recovered and discontinued immunosuppressive therapy.
Four of the 5 engrafted haploidentical HSCT recipients
developed aGVHD. Two patients were limited to grade I
aGVHD, and the other 2 had grade II aGVHD. Three of the 4
patients developed cGVHD: 1 with limited skin involvement
and the other 2 with extensive severe cGVHD of the lung. The
latter 2 patients died from complications of cGVHD (Table 1).
One of these 2 patients had received the highest CD3þ dose
in the graft, and the other patient developed severe chronic
lung GVHD after receiving a DLI.Hematologic Disease Response
All patients with sustained engraftment became
transfusion-independent with evidence of normal erythro-
poiesis, decreased hemolysis, and iron burden. Hematologic0 .2 .3 .4 1 2 3 4 5 6 7 8 9 1
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Figure 2. Disease response after MRD HSCT (solid lines) and haploidentical HSCT (da
and haploidentical HSCT for hemoglobin and hematocrit (A), hemoglobin fractions (Bresponse values after MRD and haploidentical HSCT are
presented in Table 1. After HSCT, recipients demonstrated
a signiﬁcant increase in median hemoglobin A1 levels and
decreases in median hemoglobin S and hemoglobin F levels
(Figure 2A), along with signiﬁcant increases in median total
hemoglobin and hematocrit levels (Figure 2B). Furthermore,
there was a decline in the indices of hemolysis after HSCT.
Compared with initial studies, there were signiﬁcant
decreases in median bilirubin, reticulocyte, and lactate
dehydrogenase levels (Figure 2C), along with a signiﬁcant
decrease in iron load and a nonsigniﬁcant decrease in mean
ferritin level (Figure 2D).Central Nervous System
Prospective MRI/MRA, TCD, neuropsychological testing,
and neurologic examinations were performed before and0 1 2 3 4 5 6 7 8 9 10
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Table 2
Characteristics of Patients before and after HSCT
Pre-HCST Post-HSCT Difference
Mean  SD Range Mean  SD Range Mean  SD P Value
Age, yr MRD 11.1  4.7 5.4-17.4 21.5  8.1 12-32
Haploidentical 10.3  5 4.2-17.1
Hemoglobin, g/dL MRD 7.8  1.0 6-10 14.2  1.5 11.5-17 6.3  1.0 <.0001
Haploidentical 9.6  0.6 9-10 13.6  2.9 11-16
Hematocrit, % MRD 26  5 19-32 42  5 33-48 16  6 <.0001
Haploidentical 28  1.9 26-30 40  8.3 32-49
Hemoglobin A, % MRD 33  28 0-64 59  15 47-90 26  33 .0055
Haploidentical 38  38 0-77 50.2  1 50-51
Hemoglobin S, % MRD 53  27 21-97 29  16 0-40 24  32 .0087
Haploidentical 45.4  30.8 13-75 37  1 37-38
Hemoglobin F, % MRD 6.6  5.6 1.6-22 0.4  0.6 0-1.4 6.2  5.5 .0004
Haploidentical 9.7  5.8 2.1-16 1.2  1.4 0-2.7
Reticulocytes,  103/mL MRD 293  211 104-706 90  114 29-471 168  245 .0049
Haploidentical 170  240 156-198 45  30 11-66
Bilirubin, mg/dL MRD 4.5  4.6 1.1-19.3 0.4  0.3 0.2-1.2 4.1  4.6 .0025
Haploidentical 3.2  1.3 1.7-4.1 0.3  0.3 0.1-0.6
Lactate dehydrogenase, IU/L MRD 1249  538 455-2138 181  46 129-290 1068  565 <.0001
Haploidentical 1630  708 1065-2424 220  48 188-276
Ferritin, ng/mL MRD 1722  3068 46-12,239 462  602 56-1720 1259  3121 .15
Haploidentical 1334  1001 644-2480 331  152 230-507
Iron, ng/mL MRD 132  63 44-214 91  41 34-171 35  65 .03
Haploidentical 70  27 42-96 90  38 51-128
CrCl, mL/min/1.73 m2 MRD 173  56 120-320 101  24 57-131 60  54 .004
Haploidentical 98  33 68-135 91  47 41-135
TCD, cm/s MRD 170  16 125-222 89  9 65-118 81  18 .001
Haploidentical 127  17 115-139 88 d
Shortening fraction, % MRD 42  5 34-51 37  4 28-44 37  4 .01
Haploidentical 39  2 38-41 40  2 38-42
FVC, % MRD 80  18 45-111 80  12 52-101 3  12 .80
Haploidentical 72  40 34-114 71  12 57-80
DLCO MRD 99  6 73-126 77  6 45-124 22  9 .02
Haploidentical 72  23 34-114 96  25 71-121
FEV1 MRD 73  5 36-95 78  6 41-102 5  7 .50
Haploidentical 65  14 37-82 78  2 74-80
FEV1/FVC MRD 0.93  0.18 0.66-1.16 0.95  0.21 0.66-1.34 0.02  0.09 .80
Haploidentical 0.97  1.04 0.66-1.34 1.02  0.4 0.99-1.07
Full IQ MRD 87  5 61-108 87  6 62-128 0.4  8 .90
Performance IQ MRD 94  5 70-109 85  6 63-116 9  8 .30
Verbal IQ MRD 85  6 59-106 84  4 65-108 2  6 .70
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neurologic status in children with SCD (Table 2). Neuro-
imaging before HSCT revealed evidence of cerebral infarc-
tion and vasculopathy in the patients with documented
CVA. Four patients experienced seizure activity during the
ﬁrst year after HSCT, including 1 patient with a history ofTable 3
CNS Evaluation before and after HSCT
Clinical MRI/MRA
Pre-HSCT Post-HSCT Pre-HSCT
MRD
CVA Normal Encephalomalacia; signiﬁcant stenos
CVA Normal Multiple lacunar infarcts, circle of W
CVA Normal Lacunar infarcts; moyamoya disease;
CVA Normal Small lacune; intracranial tortuosity
CVA Normal Perivascular demyelination; mild tor
CVA Seizure Lacunar infarcts; signiﬁcant stenosis
CVA Seizure Multiple lacunar infarctions; abnorm
Normal Seizure Leukoenchephalopathy; normal MRA
Normal Subarachnoid hemorrhage Normal brain; intracranial vessel tort
Normal Normal Normal brain; intracranial vessel tort
Normal Normal Mild leukoencephalopathy; normal M
Normal Normal Punctate lacune; mild stenosis
Haploidentical
CVA Normal Encephalomalacia; signiﬁcant stenos
CVA Normal Multiple lacunar infarctions; abnorm
CVA Normal Encephalomalacia; signiﬁcant stenosseizure. One patient sustained a subarachnoid hemorrhage
on day þ16 after HSCT that resolved without complica-
tions. MRI/MRA results conﬁrmed a previous ﬁnding that
parenchymal changes can continue despite normal eryth-
ropoiesis during the ﬁrst 3 years after HSCT. By 5 years
after HSCT, no patient with sustained engraftmentPost-HSCT
is Stable; normal MRA
illis occlusion Stable
severe arterio-occlusive disease Stable
Stable
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Stable
al MRA Stable
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Figure 3. IQ, renal function, and cardiac function before and after HSCT. IQ (A), renal function (B), and cardiac function (C) were monitored before (solid symbols) and
yearly after (open symbols) MRD (C,B) and haploidentical (HAPLO) (-,,) HSCT. Mean  SEM values are plotted over time after HSCT for CrCl (Bi) and shortening
fraction (Ci), and median and SEM values for CrCl (Bii) and shortening fraction (Cii) before HSCT are compared with the values measured at the most recent
evaluation.
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imaging studies. MRI showed improvement in white
matter changes, and MRA revealed stable or even
improved vessel abnormalities (Table 3). TCD studies per-
formed before and after MRD HSCT showed a signiﬁcant
decrease in maximal velocity, from 170  16 cm/s to 81 
18 cm/s (P ¼ .001) (Table 1). All TCD studies were normal
at the last evaluation. Comprehensive neuropsychiatric
evaluations were performed in 11 of the 13 patients before
and at 1, 3, and 5 years after HSCT. (Testing was limited in
2 patients in whom English was not their ﬁrst language.)The results conﬁrm stable cognitive function after HSCT,
with no signiﬁcant decreases in full, performance, or
verbal IQ scores (Table 1 and Figure 3A) .
Renal and Cardiac Function
The mean CrCl value was 158  55.7 mL/min/1.73 m2
(range, 120 to 320 mL/min/1.73 m2) in the MRD cohort and
98  33 mL/min/1.73 m2 in the haploidentical HSCT. At the
most recent evaluation, the mean CrCl in the MRD cohort
was 103.5  24 mL/min/1.73 m2 (range, 57 to 131 mL/min/
1.73 m2), for a signiﬁcant difference of 60  55 mL/min/1.73
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Figure 4. Pulmonary function before and after HSCT. PFTs, including FVC (A), DLCO (B), FEV1 (C), and FEV1/FVC ratio (D), were monitored before (solid symbols) and
yearly after (open symbols) HSCT. Mean  SEM values are plotted over time after MRD (C,B) and haploidentical (HAPLO) (-,,) HSCT for FVC (Ai) and DLCO (Bi).
The median  SEM values before HSCT or ﬁrst available values (closed symbols) are compared with the most recent value (open symbol) for FVC (Aii), DLCO (Bii), FEV1
(Ci), and FEV1/FVC ratio (Cii).
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function values decreased to below-normal levels
(Figure 3B). At the last evaluation, all patients had normal
urinanalysis results, with no proteinuria or hematuria. Before
undergoing HSCT, all patients had normal cardiac function,
with a median shortening fraction of 41% 5% (range, 34% to
51%), and at the most recent evaluations the median short-
ening fraction was 37.5%  4% (range, 28% to 44%), demon-
strating a signiﬁcant difference between the 2 time points
(P ¼ .001). No haploidentical HSCT recipient exhibited
a change in shortening fraction (Figure 3C). Three patients
had mild tricuspid insufﬁciency, and 1 patient had tracepulmonary insufﬁciency, but no patient had evidence of
pulmonary hypertension.
Pulmonary Function
Among the 16 patients treated successfully for SCD, 12
were age >6 years at the time of HSCT and had baseline PFT
data available. The other 4 patients underwent PFTs when
able to perform the studies. Three patients underwent PFTs
at 1 year after HSCT and 1 patient did so at 3 years after HSCT.
There was no signiﬁcance difference in the mean predicted
FVC, FEV1, and FEV1/FVC ratio between baseline studies and
the most recent evaluation (Table 2); however, in the MRD
Table 4
Results of Liver Spleen Scans before and after HSCT
Age Pre-HSCT, y Spleen Liver
Pre-HSCT Post-HSCT Pre-HSCT Post-HSCT
MRD 14.6 Normal Normal Normal Normal
MRD 5.8 Normal Normal Normal Normal
MRD 9.2 Minimal uptake Recovered Normal Normal
MRD 5.4 Minimal uptake Mild regeneration Normal Normal
MRD 6.0 None Mild regeneration Normal Normal
MRD 14.3 None None Normal Normal
MRD 8.8 None None Hepatomegaly Normal
MRD 10.5 None None Hepatomegaly Normal
MRD 14.5 None None Hepatomegaly Normal
Haplo 8.5 None None Normal Normal
Haplo 13.4 None None Normal Normal
Haplo 4.2 Minimal uptake Mild regeneration Normal Normal
Haplo indicates haploidentical.
M.H. Dallas et al. / Biol Blood Marrow Transplant 19 (2013) 820e830 827cohort, the mean DLCO declined from 99%  6% to 77%  7%
(P ¼ .02) after HSCT (Table 2 and Figure 4). Before HSCT, 6
patients had normal PFT values, 5 had a restrictive pattern,
and 1 had a combined restrictive/obstructive pattern. Three
of the 4 patients who underwent PFTs performed after HSCT
exhibited a restrictive pattern, whereas the other patient had
normal values. The 7 patients with normal initial PFT values
maintained normal lung function after HSCT. Among the 9
patients who had restrictive disease at the initial examina-
tion, 1 patient had improved function, 4 patients had
persistent restrictive changes, and 4 patients developed
a combined restrictive/obstructive pattern, as documented
by decreased FEV1, FVC, and FEV1/FVC ratio values.Liver and Spleen Function
Liver and spleen scans were performed in 12 patients. The
3 patients with documented splenectomy did not undergo
these studies. Three patients who had minimal splenic
uptake before HSCT demonstrated improved splenic uptake/
regeneration after HSCT. One patient with no splenic uptake
before HSCT exhibited increased splenic function, with
evidence of splenic regeneration at dayþ160 and 1 year after
HSCT. The other patients with no splenic uptake did not
recover any function. Nine patients who had a normal liver
scan before HSCT also had a normal scan at the last evalua-
tion. The 3 patients with documented mild to moderateTable 5
Osteonecrosis and BMD before and after HSCT
MRI AVN BMD Clinical
Pre-HSCT Post-HSCT Pre-HSCT Post-HSCT
Normal Normal Normal Normal
Normal Normal Mild Normal
Normal Normal Mild Normal
Normal Normal Mild Mild
Normal Normal Mild Mild
Normal Normal Mild Moderate
Normal Normal Moderate Normal
Normal Normal Moderate Mild Fracture
Normal Normal Severe BMD Moderate Osteoporosis
Knee Stable Moderate Moderate
Femoral
head
Normal Moderate Moderate
improved
Osteoporosis
Femoral
head
Normal Moderate Moderate
improved
Sacrum and
knee
Knee Severe Severe Osteoporosis and
fracturehepatomegaly before HSCT also had a normal liver scan after
HSCT (Table 4).
Hypothalamic-Pituitary (Adrenal, Thyroid, and Gonadal)
Function
Endocrine function was monitored in all survivors after
HSCT. All patients were age 12 years at the last evaluation.
The median age was 20.3  7.1 years (range, 12 to 33 years)
for the 9 males (69%) and 18.3  3.3 years (range, 15 to 22
years) for the 4 females (31%). Five of the 9 males exhibited
normal gonadal function, with normal LH, FSH, and testos-
terone levels. Three males had evidence of hypogonadism,
with elevated gonadotropin, LH, and FSH levels but normal
testosterone levels. One patient developed primary hypo-
gonadism and was started on testosterone therapy. Two of
the 4 females developed ovarian failure with elevated
gonadotropin and low estradiol levels requiring replacement
therapy. The other 2 females had normal laboratory results
and menstrual cycles, and 1 of the women was 5 months
pregnant at her last evaluation.
Growth and Bone
Growth was monitored based on skeletal bone age,
growth velocity, and somatomedin C or insulin-like growth
factor 1 levels. All 13 of the surviving patients underwent
annual skeletal bone age studies until skeletal maturation
was complete. Seven of the 13 patients (54%) had no
evidence of abnormal skeletal development detected on
initial or follow-up studies. Five of the 13 patients with
delayed bone age on the initial study exhibited normal bone
age by 2 years after HSCT. One patient with cGVHD who had
normal bone age before HSCT exhibited delayed bone age
and low/normal insulin-like growth factor 1 levels and
developed severe osteoporosis after HSCT. No survivor
demonstrated hypothyroidism or adrenal insufﬁciency at the
last evaluation. All patients had normal thyroid-stimulating
hormone, thyroxine, and free thyroxine before and after
HSCT. At the last evaluation, cortisol levels were normal in all
patients screened for adrenal insufﬁciency (n ¼ 10). Adre-
nocorticotropic hormone andmetyrpone stimulation studies
were normal in patients considered at increased risk for
insufﬁciency (n ¼ 7).
All patients underwent imaging studies (MRI or radiog-
raphy) to evaluate the risk of osteonecrosis. Before HSCT, 3
patients had evidence of avascular necrosis (AVN) at
common sites, including the femoral head, knee, and/or
sacrum; these patients had stable ﬁndings by 3 years after
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Figure 5. Bone density before and after HSCT. Whole-body (A) and vertebral body (B) BMD (i) and BMD z-scores (ii) were monitored before (solid symbols) and after
(open symbols) HSCT. Median  SEM values for the MRD (C,B) and haploidentical (HAPLO) (-,,) recipients are compared with those measured at the most recent
evaluation.
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hip) at 2 years after HSCT. By 5 years after HSCT, all patients
with AVN had stable lesions, and no additional lesions were
detected.
Osteoporosis was monitored yearly with computed
tomography bone density and dual-energy X-ray absorpti-
ometry scans (Figure 5). Themedianwhole-body BMD values
were 151  41 (range, 72 to 210) and 151  22 (range, 128 to
200), and median lumbar spine BMD values were 0.70  0.16
(range, 0.35-0.86) and 0.79  0.96 (range, 0.61 to 1.0).
Median BMD z-scores were 1.5  1.0 (range, 2.21 to 1.1)
and1.3 1.5 (range,4.6 to 1.6) for whole body and2.2
2.0 (range,5.9 to 2.0) and2.0 1.6 (range,3.5 to 2.3) for
lumbar spine.
DISCUSSION
This study is the ﬁrst comprehensive evaluation of quality
of survival after successful related-donor (haploidentical or
MSD) HSCT for SCD. Hansbury et al. [24] previously described
our institutional experience of ﬁnding an unaffected MRD
(7%) for patients with severe SCD, and the use of hap-
loidentical donors expands the pool of patients eligible for
HSCT. Here we report the long-term follow-up results of
routine assessments of organ function, particularly of the
brain, lung, heart, liver, spleen, kidney, bone, and endocrine
system.
Recipients of haploidentical HSCT had a much higher and
signiﬁcant risk for graft rejection compared with MRD HSCTrecipients. However, their risk of rejectionwas similar to that
of patients who underwent reduced-intensity conditioning
haploidentical HSCT reported by Bolaños-Meade et al. [11].
Unfortunately, we found a greater risk for GVHD, particularly
extensive cGVHD, which led to increased mortality in our
study. Our haploidentical grafts were based on CD3þ deple-
tion and CD34þ selection. Patients who received high doses
of CD3þ T cells or DLI were at signiﬁcant risk for increased
mortality. Although the small number of patients in both
studies limit conclusive results, the ﬁndings suggest that
a preparative regimen with post-transplantation cyclophos-
phamide may be more effective than T cell depletion in
preventing GVHD.
In this study, patients who successfully engrafted after
haploidentical HSCT had beneﬁcial outcomes similar to those
seen in our MRD HSCT recipients. Our ﬁndings conﬁrm that
children with CVA are protected from further CVA after
successful haploidentical HSCT. A previous report suggested
that early progressive imaging changes noted after HSCTmay
be due to the natural history of neurovascular injury,
including reactive gliosis related to the initial event [17]. It
was hypothesized that these early changes were not new
ﬁndings, but rather reﬂected the evolution of cerebrovas-
cular disease that existed before HSCT. Our study supports
these ﬁndings, with long-term follow-up demonstrating
improvement and stabilization of cerebral lacunae or leu-
koencephaly by 5 years after HSCT in both the MRD and
haploidentical donor cohorts. Furthermore, we conﬁrmed
M.H. Dallas et al. / Biol Blood Marrow Transplant 19 (2013) 820e830 829that persistent brain MRI changes were not associated with
progressive neurocognitive deﬁcits. The routine neuro-
psychologic testing showed stable neurocognitive function
with no appreciable change in IQ after HSCT. In the series
reported here, individuals with silent cerebral infarction
were protected from progressive changes on brain MRI, and
some patients experienced resolution of abnormalities
documented before HSCT. Improvements in vessel abnor-
malities documented on MRI/MRA were noted after HSCT,
with 2 patients demonstrating diminished vessel disease; all
patients with abnormal TCD velocities before HSCT had
normal velocities after HSCT.
Previous studies have reported no signiﬁcant decline in
pulmonary function after HSCT [7,13]. Here we found
a signiﬁcant decline in DLCO in our MRD cohort. We assume
that this decline is associated with busulfan toxicity rather
than with progression of vascular damage from SCD, civen
the lack of evidence of other vascular occlusive damage in the
lungs. Some patients developed decreased FEV1 level and
FEV1/FVC ratio, consistent with obstructive disease. Although
obstructive changes observed after HSCT may be associated
with the use of busulfan in the conditioning regimen [5],
a growing body of evidence suggests that the progressive
pulmonary toxicity of SCD may be restrictive or obstructive
pulmonary disease [25,26]. The available data strongly
suggest that the decline in pulmonary function due to SCD
vasculopathy is halted by the establishment of normal
erythropoiesis, regardless of donor source.
Our HSCT recipients demonstrated signiﬁcant declines in
renal function after transplantation, as demonstrated by
decreased CrCl values. Although our cohort’s median CrCl
value after HSCT was in the normal range, 2 patients had
values clearly below the normal range. Furthermore, there
was signiﬁcant difference in the median CrCl values before
HSCT and that measured at the last evaluation; however, no
patient had evidence of proteinuria or hematuria on
urinanalysis.
Although some patients had evidence of mild tricuspid
regurgitation, their jet velocities were normal, with no clin-
ical impact on cardiac function. We found no evidence of
pulmonary hypertension in any of our patients. Of the 16
patients treated successfully (median age, 20 years), 85%
were past late adolescence (>17 years), and 70% were age
>20 years. This suggests that the abrogation of hemolysis by
successful HSCT decreases the risk of developing pulmonary
hypertension in patients with SCD.
Patients with SCD are at increased risk for AVN and
osteoporosis [27]. Most of our patients had signiﬁcant oste-
oporosis with very low BMD values before HSCT. Patients
with documented AVN before HSCT demonstrated some
improvement after HSCT, but although BMD and BMD z-
score values increased after HSCT, these patients remained at
high risk for osteoporosis. Furthermore, females with hypo-
gonadism had signiﬁcant osteoporosis unless treated with
hormone therapy. Hip MRI performed before HSCT docu-
mented abnormal marrow intensity associated with SCD.
These ﬁndings were all normalized after HSCT. In summary,
we observed improvement of AVN with modest increase in
BMD after both MRD and haploidentical donor HSCT.
Our patients with delayed bone growth all demonstrated
normalized growth after HSCT, if not complicated by cGVHD.
Endocrine function studies showed no increased risk for
thyroid or adrenal insufﬁciency; however, a signiﬁcant
proportion of patients (30%) developed gonadal insufﬁciency
after HSCT and required treatment with hormonereplacement therapy. Taken together, these observations
tend to conﬁrm the gonadal toxicity associated with expo-
sure to myeloablative doses of busulfan [6].
In summary, HSCT offers long-term protection from
clinical and subclinical vaso-occlusion associated with SCD,
regardless of donor source. Complications that commonly
develop in patients with SCD, including stroke, pulmonary
hypertension, acute chest, proteinuria, and hematuria, were
not observed in our patients after successful HSCT; however,
the patients who underwent myeloablative MRD HSCT
demonstrated progressive declines in renal, pulmonary, and
cardiac function over time that have not been reported
previously. Our data suggest that the declining organ func-
tion is likely due to the conditioning regimens rather than to
complications of SCD. Whether patients with SCD are at
greater risk for declining organ function, and whether
reduced-intensity conditioning regimens may offer better
outcomes after HSCT, require additional investigation.
Although our study was limited by number of patients, 100%
of the patients underwent extensive pre- and post-HSCT
evaluation. This might have facilitated the better detection
of declining organ function compared with large retrospec-
tive multi-institutional studies. We hope that this report
encourages further long-term evaluations in patients
undergoing reduced-intensity haploidentical HSCT for SCD
to examine whether organ function is better preserved with
this modality compared with conventional MRD HSCT.ACKNOWLEDGMENTS
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